Study platform ArcHIV - Substudy on SARS-CoV-2 (COVID-19) IgG antibody prevalence in an HIV cohort

• Conditions: Prevalence of Sars-Cov-2-IgG in HIV-infected pople; B20-B24; U07.1; Human immunodeficiency virus [HIV] disease; COVID-19, virus identified

• Registration Number: DRKS00021752
• Lead Sponsor: MUC Research GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-28
• Study Completion: 2020-07-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Patient is already a study participant in ArcHIV, the signed patient information with consent and privacy declaration for this substudy

Exclusion Criteria

Patient is not a study participant of the study platform ArcHIV, patient <18 years, Patient has no present signed consent and privacy statement of the substudy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary goal of the ArcHIV substudy is to evaluate the presence of IgG antibodies against SARS-CoV-2 - as a prevalence estimate of previous infections - in an HIV population.

Secondary Outcome Measures

Name	Time	Method
Secondary objectives are the description of SARS-CoV-2-IgG prevalence with regard to SARS-CoV-2 anamnesis (already proven SARS-CoV-2 infections) or the known SARS-CoV-2 exposure in this HIV cohort and the description of HIV-specific characteristics including antiretroviral therapy